

REMARKS

The Examiner has indicated that claim 1 is allowed and that claims 2-5 have been rejoined. Claims 2 and 4 have been amended to remove the term "prevention". No new matter is added. For the reasons that follow, Applicants believe all claims are now in condition for allowance and respectfully request that a Notice of Allowance be issued.

35 U.S.C. §112, 1st paragraph

Claims 2-5 are rejected as allegedly not satisfying the enablement requirement under 35 U.S.C. §112, 1st paragraph (see Office Action, pp. 2-7). In particular, the Examiner asserts that although the claims are enabled for "treating" conditions mediated by avβ3 and/or avβ5, they are not enabled for "preventing" such conditions (see Office Action, pp. 2-3). Although Applicants disagree with the Examiner's position, in order to advance prosecution, claims 2 and 4 have been amended to remove the term "prevention". Accordingly, because the Examiner has acknowledged that claims 2-5 are enabled with regard to "treating", Applicants believe that the claims as amended are now in condition for allowance and respectfully request that the rejection under 35 U.S.C. §112, 1st paragraph be withdrawn.

35 U.S.C. §112, 2nd paragraph

Claims 2-5 are rejected for allegedly being indefinite under 35 U.S.C. §112, 2nd paragraph (see Office Action, p. 7). In particular, the Examiner asserts that the term "therapeutically effective" is not defined and that one of ordinary skill in the art would not understand the scope of the invention. Applicants disagree and would like to point the Examiner's attention to the explicit definition for the term "therapeutically effective amount" found in paragraph 567 (see p. 22 of US 2005-0043344). Applicants contend that this definition is adequate and that those skilled in the art would understand the meaning of this term as it is defined in the specification. Accordingly, Applicants request that the rejection under 35 U.S.C. §112, 2nd paragraph be withdrawn.

Conclusion

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the satisfaction of the Examiner, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Attorney Docket No. PC31766A
Application No. 10/743,354
Conf. No. 9317

Respectfully submitted,

Date: September 6, 2006

/Matthew J. Pugmire/

Matthew J. Pugmire
Attorney for Applicants
Registration No. 54,723

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 638-6349
Fax: (858) 678-8233